Virginia Espina

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/38569/publications.pdf

Version: 2024-02-01

		36303	27406
157	11,793	51	106
papers	citations	h-index	g-index
161	161	161	19247
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	9.1	3,122
2	Laser-capture microdissection. Nature Protocols, 2006, 1, 586-603.	12.0	651
3	Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 14229-14234.	7.1	463
4	Protein microarrays: Meeting analytical challenges for clinical applications. Cancer Cell, 2003, 3, 317-325.	16.8	439
5	Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. Journal of Clinical Investigation, 2005, 115, 1163-1176.	8.2	338
6	Use of Reverse Phase Protein Microarrays and Reference Standard Development for Molecular Network Analysis of Metastatic Ovarian Carcinoma. Molecular and Cellular Proteomics, 2005, 4, 346-355.	3.8	278
7	Phosphoprotein Pathway Mapping: Akt/Mammalian Target of Rapamycin Activation Is Negatively Associated with Childhood Rhabdomyosarcoma Survival. Cancer Research, 2007, 67, 3431-3440.	0.9	230
8	Protein microarrays: Molecular profiling technologies for clinical specimens. Proteomics, 2003, 3, 2091-2100.	2.2	227
9	Tumorigenic and Metastatic Activity of Human Thyroid Cancer Stem Cells. Cancer Research, 2010, 70, 8874-8885.	0.9	197
10	A Portrait of Tissue Phosphoprotein Stability in the Clinical Tissue Procurement Process. Molecular and Cellular Proteomics, 2008, 7, 1998-2018.	3.8	187
11	Safety and Biologic Response of Pre-operative Autophagy Inhibition in Combination with Gemcitabine in Patients with Pancreatic Adenocarcinoma. Annals of Surgical Oncology, 2015, 22, 4402-4410.	1.5	187
12	Smart Hydrogel Particles:  Biomarker Harvesting:  One-Step Affinity Purification, Size Exclusion, and Protection against Degradation. Nano Letters, 2008, 8, 350-361.	9.1	182
13	Protein microarray detection strategies: focus on direct detection technologies. Journal of Immunological Methods, 2004, 290, 121-133.	1.4	171
14	Mapping Molecular Networks Using Proteomics: A Vision for Patient-Tailored Combination Therapy. Journal of Clinical Oncology, 2005, 23, 3614-3621.	1.6	170
15	Laser capture microdissection technology. Expert Review of Molecular Diagnostics, 2007, 7, 647-657.	3.1	161
16	Serum Proteomics in Cancer Diagnosis and Management. Annual Review of Medicine, 2004, 55, 97-112.	12.2	141
17	A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer, 2007, 109, 1323-1330.	4.1	134
18	A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients. Clinical Cancer Research, 2020, 26, 3126-3134.	7.0	133

#	Article	IF	CITATIONS
19	Multiplexed Cell Signaling Analysis of Human Breast Cancer Applications for Personalized Therapy. Journal of Proteome Research, 2008, 7, 1508-1517.	3.7	128
20	Reverse phase protein microarrays advance to use in clinical trials. Molecular Oncology, 2010, 4, 461-481.	4.6	126
21	Pegylated, Steptavidin-Conjugated Quantum Dots Are Effective Detection Elements for Reverse-Phase Protein Microarrays. Bioconjugate Chemistry, 2005, 16, 559-566.	3.6	124
22	Malignant Precursor Cells Pre-Exist in Human Breast DCIS and Require Autophagy for Survival. PLoS ONE, 2010, 5, e10240.	2.5	124
23	CSF proteome: a protein repository for potential biomarker identification. Expert Review of Proteomics, 2005, 2, 57-70.	3.0	113
24	Molecular Analysis of HER2 Signaling in Human Breast Cancer by Functional Protein Pathway Activation Mapping. Clinical Cancer Research, 2012, 18, 6426-6435.	7.0	110
25	Clinical Proteomics:Â Revolutionizing Disease Detection and Patient Tailoring Therapy. Journal of Proteome Research, 2004, 3, 209-217.	3.7	108
26	Proteomic Analysis of Apoptotic Pathways Reveals Prognostic Factors in Follicular Lymphoma. Clinical Cancer Research, 2005, 11, 5847-5855.	7.0	105
27	Retinal pigment epithelium (RPE) exosomes contain signaling phosphoproteins affected by oxidative stress. Experimental Cell Research, 2013, 319, 2113-2123.	2.6	105
28	Laser Capture Microdissection and Protein Microarray Analysis of Human Non-small Cell Lung Cancer. Molecular and Cellular Proteomics, 2008, 7, 1902-1924.	3.8	103
29	Current state of the art for enhancing urine biomarker discovery. Expert Review of Proteomics, 2016, 13, 609-626.	3.0	101
30	Core-Shell Hydrogel Particles Harvest, Concentrate and Preserve Labile Low Abundance Biomarkers. PLoS ONE, 2009, 4, e4763.	2.5	92
31	Multifunctional Core–Shell Nanoparticles: Discovery of Previously Invisible Biomarkers. Journal of the American Chemical Society, 2011, 133, 19178-19188.	13.7	90
32	What is the malignant nature of human ductal carcinoma in situ?. Nature Reviews Cancer, $2011, 11, 68-75$.	28.4	89
33	Genomic and proteomic technologies for individualisation and improvement of cancer treatment. European Journal of Cancer, 2004, 40, 2623-2632.	2.8	86
34	Use of proteomic analysis to monitor responses to biological therapies. Expert Opinion on Biological Therapy, 2004, 4, 83-93.	3.1	85
35	Tissue is alive: New technologies are needed to address the problems of protein biomarker preâ€analytical variability. Proteomics - Clinical Applications, 2009, 3, 874-882.	1.6	79
36	The needle in the haystack: Application of breast fine-needle aspirate samples to quantitative protein microarray technology. Cancer, 2007, 111, 173-184.	4.1	78

3

#	Article	IF	Citations
37	Reverse-phase protein microarrays: application to biomarker discovery and translational medicine. Expert Review of Molecular Diagnostics, 2007, 7, 625-633.	3.1	77
38	Proteomic Analysis of Malignant Ovarian Cancer Effusions as a Tool for Biologic and Prognostic Profiling. Clinical Cancer Research, 2006, 12, 791-799.	7.0	75
39	Accurate diagnosis of acute graft-versus-host disease using serum proteomic pattern analysis. Experimental Hematology, 2006, 34, 796-801.	0.4	74
40	Biomarkers of ovarian tumours. European Journal of Cancer, 2004, 40, 2604-2612.	2.8	72
41	One-Step Preservation of Phosphoproteins and Tissue Morphology at Room Temperature for Diagnostic and Research Specimens. PLoS ONE, 2011, 6, e23780.	2.5	71
42	PMCA2 regulates HER2 protein kinase localization and signaling and promotes HER2-mediated breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E282-90.	7.1	70
43	Physicochemically modified silicon as a substrate for protein microarrays. Biomaterials, 2007, 28, 550-558.	11.4	66
44	Protein biomarkers for subtyping breast cancer and implications for future research. Expert Review of Proteomics, 2018, 15, 131-152.	3.0	63
45	Pathology of the Future: Molecular Profiling for Targeted Therapy. Cancer Investigation, 2005, 23, 36-46.	1.3	61
46	Quantitative cell signalling analysis reveals downâ€regulation of MAPK pathway activation in colorectal cancer. Journal of Pathology, 2009, 218, 514-519.	4.5	60
47	A prospective analysis of imatinib-induced c-kit modulation in ovarian cancer. Cancer, 2007, 110, 309-317.	4.1	59
48	Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling. BMC Research Notes, 2013, 6, 507.	1.4	59
49	A Transforming Growth Factor-β Receptor–Interacting Protein Frequently Mutated in Human Ovarian Cancer. Cancer Research, 2005, 65, 6526-6533.	0.9	58
50	Laser Capture Microdissection. Methods in Molecular Biology, 2006, 319, 213-229.	0.9	56
51	Concentration and preservation of very low abundance biomarkers in urine, such as human growth hormone (hGH), by Cibacron Blue F3G-A loaded hydrogel particles. Nano Research, 2008, 1, 502-518.	10.4	55
52	The use of hydrogel microparticles to sequester and concentrate bacterial antigens in a urine test for Lyme disease. Biomaterials, 2011, 32, 1157-1166.	11.4	52
53	The Heme Degradation Pathway is a Promising Serum Biomarker Source for the Early Detection of Alzheimer's Disease, 2010, 19, 1081-1091.	2.6	50
54	Students Who Demonstrate Strong Talent and Interest in STEM Are Initially Attracted to STEM through Extracurricular Experiences. CBE Life Sciences Education, 2014, 13, 687-697.	2.3	50

#	Article	IF	Citations
55	Reverse-Phase Phosphoproteome Analysis of Signaling Pathways Induced by Rift Valley Fever Virus in Human Small Airway Epithelial Cells. PLoS ONE, 2010, 5, e13805.	2.5	49
56	Laser Capture Microdissection for Protein and NanoString RNA Analysis. Methods in Molecular Biology, 2012, 931, 213-257.	0.9	49
57	A novel biomarker harvesting nanotechnology identifies Bak as a candidate melanoma biomarker in serum. Experimental Dermatology, 2011, 20, 29-34.	2.9	46
58	Application of Nanotrap technology for high sensitivity measurement of urinary outer surface protein A carboxyl-terminus domain in early stage Lyme borreliosis. Journal of Translational Medicine, 2015, 13, 346.	4.4	46
59	Protein painting reveals solvent-excluded drug targets hidden within native protein–protein interfaces. Nature Communications, 2014, 5, 4413.	12.8	45
60	Glioblastoma Cell Enrichment Is Critical for Analysis of Phosphorylated Drug Targets and Proteomic–Genomic Correlations. Cancer Research, 2014, 74, 818-828.	0.9	44
61	Functional Protein Network Activation Mapping Reveals New Potential Molecular Drug Targets for Poor Prognosis Pediatric BCP-ALL. PLoS ONE, 2010, 5, e13552.	2.5	42
62	Reverse Phase Protein Arrays: Mapping the Path Towards Personalized Medicine. Molecular Diagnosis and Therapy, 2014, 18, 619-630.	3.8	39
63	Activated VEGF Receptor Shed Into the Vitreous in Eyes With Wet AMD. JAMA Ophthalmology, 2009, 127, 613.	2.4	37
64	Reverse-Phase Protein Microarrays for Theranostics and Patient Tailored Therapy. Methods in Molecular Biology, 2009, 520, 89-105.	0.9	35
65	Effects of HER Family–targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer. Clinical Cancer Research, 2021, 27, 807-818.	7.0	34
66	Expression of xeroderma pigmentosum A protein predicts improved outcome in metastatic ovarian carcinoma. Cancer, 2005, 103, 2313-2319.	4.1	32
67	Elevated TNFR1 and Serotonin in Bone Metastasis Are Correlated with Poor Survival following Bone Metastasis Diagnosis for Both Carcinoma and Sarcoma Primary Tumors. Clinical Cancer Research, 2013, 19, 2473-2485.	7.0	31
68	Application of Laser Microdissection and Reverse-Phase Protein Microarrays to the Molecular Profiling of Cancer Signal Pathway Networks in the Tissue Microenvironment. Clinics in Laboratory Medicine, 2009, 29, 1-13.	1.4	30
69	Use of proteomic patterns to screen for gastrointestinal malignancies. Surgery, 2004, 135, 243-247.	1.9	29
70	Comparison of Global versus Epidermal Growth Factor Receptor Pathway Profiling for Prediction of Lapatinib Sensitivity in Bladder Cancer. Neoplasia, 2009, 11, 1185-IN20.	5.3	29
71	Local production of lactate, ribose phosphate, and amino acids by human triple-negative breast cancer. Med, 2021, 2, 736-754.e6.	4.4	28
72	High CerS5 expression levels associate with reduced patient survival and transition from apoptotic to autophagy signalling pathways in colorectal cancer. Journal of Pathology: Clinical Research, 2015, 1, 54-65.	3.0	27

#	Article	IF	CITATIONS
73	Improved data normalization methods for reverse phase protein microarray analysis of complex biological samples. BioTechniques, 2012, 0, 1-7.	1.8	27
74	Reverse Phase Protein Microarrays for Monitoring Biological Responses., 2007, 383, 321-336.		26
75	Laser Capture Microdissection: ArcturusXT Infrared Capture and UV Cutting Methods. Methods in Molecular Biology, 2012, 823, 157-178.	0.9	26
76	Nanoparticle technology: amplifying the effective sensitivity of biomarker detection to create a urine test for hGH. Drug Testing and Analysis, 2009, 1, 447-454.	2.6	25
77	Phosphoprotein Stability in Clinical Tissue and Its Relevance for Reverse Phase Protein Microarray Technology. Methods in Molecular Biology, 2011, 785, 23-43.	0.9	24
78	Anthrax infection inhibits the AKT signaling involved in the E-cadherin-mediated adhesion of lung epithelial cells. FEMS Immunology and Medical Microbiology, 2009, 56, 129-142.	2.7	23
79	Nanoparticle technology: Addressing the fundamental roadblocks to protein biomarker discovery. Journal of Materials Chemistry, 2009, 19, 5071.	6.7	23
80	Reverse Phase Protein Microarrays for Theranostics and Patient-Tailored Therapy. Methods in Molecular Biology, 2008, 441, 113-128.	0.9	23
81	Inhibition of histone deacetylase 4 increases cytotoxicity of docetaxel in gastric cancer cells. Proteomics - Clinical Applications, 2014, 8, 924-931.	1.6	22
82	Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL. BMC Cancer, 2018, 18, 965.	2.6	21
83	Mapping protein signal pathway interaction in sarcoma bone metastasis: linkage between rank, metalloproteinases turnover and growth factor signaling pathways. Clinical and Experimental Metastasis, 2014, 31, 15-24.	3.3	20
84	Reverse Phase Protein Microarrays: Fluorometric and Colorimetric Detection. Methods in Molecular Biology, 2011, 723, 275-301.	0.9	20
85	Molecular Diagnostics. Hematology American Society of Hematology Education Program, 2003, 2003, 279-293.	2.5	19
86	Proteomic Analysis Reveals Autophagy as Pro-Survival Pathway Elicited by Long-Term Exposure with 5-Azacitidine in High-Risk Myelodysplasia. Frontiers in Pharmacology, 2017, 8, 204.	3.5	19
87	Laser Capture Proteomics: spatial tissue molecular profiling from the bench to personalized medicine. Expert Review of Proteomics, 2021, 18, 845-861.	3.0	19
88	Rapamycin modulation of p70 S6 kinase signaling inhibits Rift Valley fever virus pathogenesis. Antiviral Research, 2017, 143, 162-175.	4.1	17
89	Molecular Network Analysis using Reverse Phase Protein Microarrays for Patient Tailored Therapy. Advances in Experimental Medicine and Biology, 2008, 610, 177-186.	1.6	17
90	Automated Laser Capture Microdissection for Tissue Proteomics. Methods in Molecular Biology, 2008, 441, 71-90.	0.9	17

#	Article	IF	CITATIONS
91	Pathology-Driven Comprehensive Proteomic Profiling of the Prostate Cancer Tumor Microenvironment. Molecular Cancer Research, 2017, 15, 281-293.	3.4	16
92	A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib. Oncotarget, 2017, 8, 85120-85135.	1.8	15
93	An Interventional Magnetic Resonance Imaging Technique for the Molecular Characterization of Intraprostatic Dynamic Contrast Enhancement. Molecular Imaging, 2005, 4, 153535002005041.	1.4	14
94	Reduction of Preanalytical Variability in Specimen Procurement for Molecular Profiling. Methods in Molecular Biology, 2012, 823, 49-57.	0.9	14
95	APPLICATION OF LASER CAPTURE MICRODISSECTION AND PROTEIN MICROARRAY TECHNOLOGIES IN THE MOLECULAR ANALYSIS OF AIRWAY INJURY FOLLOWING POLLUTION PARTICLE EXPOSURE. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2004, 67, 851-861.	2.3	13
96	RPPA: Origins, Transition to a Validated Clinical Research Tool, and Next Generations of the Technology. Advances in Experimental Medicine and Biology, 2019, 1188, 1-19.	1.6	13
97	Nitric oxide as a regulator of B. anthracis pathogenicity. Frontiers in Microbiology, 2015, 6, 921.	3 . 5	12
98	Encouraging longâ€term survival following autophagy inhibition using neoadjuvant hydroxychloroquine and gemcitabine for highâ€risk patients with resectable pancreatic carcinoma. Cancer Medicine, 2021, 10, 7233-7241.	2.8	12
99	Development of reverse phase protein microarrays for clinical applications and patient-tailored therapy. Cancer Genomics and Proteomics, 2007, 4, 157-64.	2.0	12
100	Different measures of HMGB1 location in cancer immunology. Methods in Enzymology, 2019, 629, 195-217.	1.0	11
101	Chemokine-Releasing Nanoparticles for Manipulation of the Lymph Node Microenvironment. Nanomaterials, 2015, 5, 298-320.	4.1	10
102	Potential anti-cancer activity of 7- O -pentyl quercetin: Efficient, membrane-targeted kinase inhibition and pro-oxidant effect. Pharmacological Research, 2017, 124, 9-19.	7.1	10
103	A new model isolates glioblastoma clonal interactions and reveals unexpected modes for regulating motility, proliferation, and drug resistance. Scientific Reports, 2019, 9, 17380.	3.3	10
104	Whole Proteome Analysis of Mouse Lymph Nodes in Cutaneous Anthrax. PLoS ONE, 2014, 9, e110873.	2.5	10
105	Stratification of clear cell renal cell carcinoma by signaling pathway analysis. Expert Review of Proteomics, 2014, 11, 237-249.	3.0	9
106	Hydrogel Nanoparticle Harvesting of Plasma or Urine for Detecting Low Abundance Proteins. Journal of Visualized Experiments, 2014, , e51789.	0.3	9
107	Proteomics for cancer drug design. Expert Review of Proteomics, 2019, 16, 647-664.	3.0	9
108	Beyond Punishment: Doping, Deterrence, and Moral Disengagement. , 2012, 02, .		9

#	Article	IF	Citations
109	Attacking Breast Cancer at the Preinvasion Stage by Targeting Autophagy. Women's Health, 2013, 9, 157-170.	1.5	8
110	Stromal TRIM28-associated signaling pathway modulation within the colorectal cancer microenvironment. Journal of Translational Medicine, 2018, 16, 89.	4.4	8
111	Lipoarabinomannan antigenic epitope differences in tuberculosis disease subtypes. Scientific Reports, 2020, 10, 13944.	3.3	8
112	Evaluation of pathogen specific urinary peptides in tick-borne illnesses. Scientific Reports, 2020, 10, 19340.	3.3	8
113	Protocol for the Mason: Health Starts Here prospective cohort study of young adult college students. BMC Public Health, 2021, 21, 897.	2.9	8
114	Pathology of the future: molecular profiling for targeted therapy. Cancer Investigation, 2005, 23, 36-46.	1.3	8
115	Manual exfoliation of fresh tissue obviates the need for frozen sections for molecular profiling. Cancer, 2005, 105, 483-491.	4.1	7
116	Chloroquine enjoys a renaissance as an antineoplastic therapy. Clinical Investigation, 2013, 3, 743-761.	0.0	7
117	An interventional magnetic resonance imaging technique for the molecular characterization of intraprostatic dynamic contrast enhancement. Molecular Imaging, 2005, 4, 63-6.	1.4	7
118	Ductal Carcinoma In Situ: Challenges, Opportunities, and Uncharted Waters. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 40-44.	3.8	6
119	Reverse-Phase Microarray Analysis Reveals Novel Targets in Lymph Nodes of Bacillus anthracis Spore-Challenged Mice. PLoS ONE, 2015, 10, e0129860.	2.5	6
120	Chemokine-Releasing Microparticles Improve Bacterial Clearance and Survival of Anthrax Spore-Challenged Mice. PLoS ONE, 2016, 11, e0163163.	2.5	5
121	Unlocking bone for proteomic analysis and FISH. Laboratory Investigation, 2019, 99, 708-721.	3.7	5
122	Application of sector protein microarrays to clinical samples. Clinical Proteomics, 2004, 1, 91-99.	2.1	4
123	Dual-Color, Multiplex Analysis of Protein Microarrays for Precision Medicine. Methods in Molecular Biology, 2017, 1550, 149-170.	0.9	4
124	Combination Kinase Inhibitor Treatment Suppresses Rift Valley Fever Virus Replication. Viruses, 2018, 10, 191.	3.3	4
125	<p>Tumor-Draining Lymph Secretome En Route to the Regional Lymph Node in Breast Cancer Metastasis</p> . Breast Cancer: Targets and Therapy, 2020, Volume 12, 57-67.	1.8	4
126	Proteomic Analysis of Cardioembolic and Large Artery Atherosclerotic Clots Using Reverse Phase Protein Array Technology Reveals Key Cellular Interactions Within Clot Microenvironments. Cureus, 2021, 13, e13499.	0.5	4

#	Article	IF	CITATIONS
127	Pathology of the Future: Molecular Profiling for Targeted Therapy. Cancer Investigation, 2005, 23, 36-46.	1.3	4
128	Proteomic and Genomic Profile of High-Risk MDS After Treatment with 5-Azacytidine,. Blood, 2011, 118, 3818-3818.	1.4	4
129	Persistent CD49d engagement in circulating CLL cells: a role for blood-borne ligands?. Leukemia, 2016, 30, 513-517.	7.2	3
130	Role of proteomics in personalized medicine. Personalized Medicine, 2006, 3, 223-226.	1.5	2
131	Clinical phosphoproteomic profiling for personalized targeted medicine using reverse phase protein microarray. Targeted Oncology, 2006, $1,151.$	3.6	2
132	Clinical Proteomics and Molecular Pathology. , 2009, , 165-183.		2
133	One-Step Preservation and Decalcification of Bony Tissue for Molecular Profiling. Methods in Molecular Biology, 2017, 1606, 85-102.	0.9	2
134	Comutation of PIK3CA and TP53 in Residual Disease After Preoperative Anti-HER2 Therapy in ERBB2 (HER2)-Amplified Early Breast Cancer. JCO Precision Oncology, 2019, 3, 1-26.	3.0	2
135	Reverse Phase Protein Arrays. Methods in Molecular Biology, 2021, 2237, 103-122.	0.9	2
136	Protein pathway analysis in Clinical Proteomics using protein microarrays. Drug Discovery Today: Technologies, 2005, 2, 353-359.	4.0	1
137	Treatment and Long-Term Risks for Patients With a Diagnosis of Ductal Carcinoma In Situ. JAMA Oncology, 2016, 2, 395.	7.1	1
138	Immune-modulating Activity of Hydrogel Microparticles Contributes to the Host Defense in a Murine Model of Cutaneous Anthrax. Frontiers in Molecular Biosciences, 2017, 4, 62.	3.5	1
139	Characterization and Validation of Arg286 Residue of IL-1RAcP as a Potential Drug Target for Osteoarthritis. Frontiers in Chemistry, 2020, 8, 601477.	3.6	1
140	Laser Capture Microdissection. , 2006, , 339-344.		1
141	Clinical Proteomics and Molecular Pathology. , 2010, , 113-123.		0
142	2.29 Circulating CLL Cells Expressing Markers of Clinical Aggressiveness Display a Phosphoproteomic Profile Consistent with a Constitutive Receptor Engagement. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, S177-S178.	0.4	0
143	Applications of Proteomics to Metastasis Diagnosis and Individualized Therapy., 0,, 475-485.		0
144	A response to the two faces of autophagy in DCIS. Nature Reviews Cancer, 2011, 11, 618-618.	28.4	0

#	Article	IF	CITATIONS
145	Reverse Phase Protein Microarray Technology. , 2013, , 349-361.		O
146	Non-enzymatic, Serum-free Tissue Culture of Pre-invasive Breast Lesions for Spontaneous Generation of Mammospheres. Journal of Visualized Experiments, 2014, , e51926.	0.3	0
147	Clinical Proteomics and Molecular Pathology. , 2018, , 183-203.		0
148	Clinical proteomics and molecular pathology. , 2020, , 149-163.		0
149	Protein Microarrays., 2004,, 1083-1088.		0
150	Proteomics of breast cancer., 2006, , 101-113.		0
151	Alterations of Cell Signaling Pathways in Pediatric B-ALL Patients Blood, 2006, 108, 4427-4427.	1.4	0
152	Clinical Proteomics., 2008,, 231-239.		0
153	Ex Vivo Multiplexed Signal Pathway Inhibitor Treatment Reveals Differential Sensitivity of Myeloma and Non-Myeloma Bone Marrow Cell Populations Blood, 2009, 114, 2860-2860.	1.4	0
154	Treatment with TKIs Overcomes Imatinib Resistance through the PLCgamma-1 Signaling Pathway In Imatinib Resistant Human CML Cell Lines. Blood, 2010, 116, 4468-4468.	1.4	0
155	Serotonin Dysregulation Correlates with Both Bone and Active Disease In Multiple Myeloma. Blood, 2010, 116, 1920-1920.	1.4	0
156	Circulating CLL Cells Expressing CD49d Display a Phospho-Proteomic Profile Consistent with a Constitutive Receptor Engagement by Blood-Borne Ligands. Blood, 2012, 120, 930-930.	1.4	0
157	Solid Pin Protein Array Printing Platforms. Advances in Experimental Medicine and Biology, 2019, 1188, 61-75.	1.6	O